<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850418</url>
  </required_header>
  <id_info>
    <org_study_id>12592</org_study_id>
    <nct_id>NCT03850418</nct_id>
  </id_info>
  <brief_title>Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant</brief_title>
  <official_title>Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies provide a rationale for administration of AZA after allo SCT for decreasing&#xD;
      chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and&#xD;
      help decrease rate of decreasing donor chimerism and hence decrease relapse without&#xD;
      increasing GVHD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">February 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of increase or stable donor chimerism</measure>
    <time_frame>one year</time_frame>
    <description>To determine the rate of increase or stable donor chimerism when using low dose azacitidine post allogenic stem cell transplant (SCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms (MPN) with documented low or decreasing donor chimerism</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Myeloid Malignancy</condition>
  <arm_group>
    <arm_group_label>AZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated</description>
    <arm_group_label>AZA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with AML/MDS/MPN, CMML post Allogeneic SCT who experience any drop in total&#xD;
             or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor&#xD;
             chimerism is below 98% without concurrent hematologic relapse (that is, patients with&#xD;
             &lt;5% bone marrow blasts as obtained at that time point) will be offered treatment with&#xD;
             azacitidine&#xD;
&#xD;
          2. &gt;=30 -180 days post SCT and patients must have ANC&gt; 1000, PLT &gt; 50,000&#xD;
&#xD;
          3. Age 18-75 years old&#xD;
&#xD;
          4. Performance score of at least 70% by Karnofsky&#xD;
&#xD;
          5. Adequate kidney and liver function as demonstrated by:&#xD;
&#xD;
               1. Creatinine clearance should be &gt;60 ml/min&#xD;
&#xD;
               2. Total Bilirubin &lt;1.5, ALT/AST/Alk Phos &lt; 2.5 x normal. No evidence of chronic&#xD;
                  active hepatitis or cirrhosis.&#xD;
&#xD;
          6. Negative Beta HCG test in a woman with child bearing potential, defined as not&#xD;
             post-menopausal for 12 months or no previous surgical sterilization. Women of child&#xD;
             bearing potential must be willing to use an effective contraceptive measure while on&#xD;
             study.&#xD;
&#xD;
          7. Patient or patient's legal representative, parent(s) or guardian able to sign informed&#xD;
             consent.&#xD;
&#xD;
          8. Patients must be off any prior chemotherapy, radiotherapy, or other investigational&#xD;
             therapy within 2 weeks prior to start treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause&#xD;
&#xD;
          2. Active or prior CNS leukemia, unless in complete remission for at least 2 months.&#xD;
&#xD;
          3. History of serious chronic mental disorder or drug-abuse accompanied by documented&#xD;
             problems of compliance with therapeutic programs.&#xD;
&#xD;
          4. Uncontrolled infection&#xD;
&#xD;
          5. Grade III, IV graft versus host disease (GVHD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shatha farhan, MD</last_name>
    <phone>313 916 5002</phone>
    <email>SFARHAN1@HFHS.ORG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NALINI JANAKIRAMAN, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry ford hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shatha farhan</last_name>
      <phone>313-916-5002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Shatha Farhan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

